Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities
Notice Number:
NOT-MD-22-006

Key Dates

Release Date:

December 21, 2021

First Available Due Date:
February 05, 2022
Expiration Date:
January 08, 2023

Related Announcements

February 04, 2022 - Notice of NIAMS' Participation in NOT-MD-22-006. See Notice NOT-AR-22-017.

PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

NOT-MD-21-008 (to be rescinded) - Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

NOT-DA-22-002 Notice of NIDA's Participation in NOT-MD-22-006

NOT-HL-22-012 Notice of NHLBI Participation in NOT-MD-22-006

Issued by

National Institute on Minority Health and Health Disparities (NIMHD)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute of Nursing Research (NINR)

National Cancer Institute (NCI)

National Institute on Drug Abuse ( NIDA )

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

National Heart, Lung, and Blood Institute ( NHLBI )

Office of Behavioral and Social Sciences Research (OBSSR)

Sexual and Gender Minority Research Office (SGMRO)

Office of Research on Women's Health (ORWH)

Purpose

This Notice of Special Interest (NOSI) highlights the need for research on strategies, and interventions to address vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the US and its territories. Research is needed to understand and address misinformation, distrust, and hesitancy regarding uptake of vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV)) among adults in the United States and territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions. This NOSI is focused on adults 18 years and older except for SARS-CoV-2 and HPV-related vaccine topics, which may include eligible children and adolescents. The purpose of this NOSI is to solicit research to: 1) evaluate community-engaged interventions (e.g., expand reach, increase access, address psychosocial barriers) to facilitate vaccination uptake in clinical and community contexts; 2) evaluate organizational, local, state, and federal policies and initiatives that mitigate or exacerbate disparities in vaccine access, uptake, and series completion, and 3) understand and address barriers to increasing reach, access, and uptake of vaccinations among populations who experience health disparities.

Background and Goals

United States Food and Drug Administration (FDA)-authorized/approved vaccines and boosters, along with effective mitigation and prevention strategies, are critical for reducing rates of infection and slowing the spread of infectious diseases. Viral outbreaks of preventable diseases, such as SARS-CoV-2 (COVID-19) and substantial levels of vaccine hesitancy among populations with health disparities, highlight the need to develop and evaluate strategies and policies to increase vaccine completion. NIH is committed to advancing scientific knowledge on methods to increase access to and uptake of vaccinations to prevent life-threatening illnesses.

There is evidence of disparities in the acceptance and uptake of other vaccinations among adults from racial and ethnic minority populations, including vaccines for influenza, pneumococcal, and HPV. For instance, research on influenza vaccination uptake shows a pattern of racial and ethnic minority persons being less likely to receive the vaccine, with socioeconomic and clinician/health care system factors as possible contributors. Research on HPV vaccination uptake shows a similar pattern of racial/ethnic minority persons being less likely to initiate or complete the series. Vaccine hesitancy is comprised of one’s confidence in the safety and efficacy of the vaccines, complacency towards vaccine uptake/completion, and convenience in accessing the vaccine. For some vaccines, hesitancy is higher for populations experiencing health disparities. The reasons for hesitancy are varied, but may include concerns about perceived safety, skepticism about the trustworthiness of the source(s) of vaccination recommendations, exposure to misinformation and disinformation, considering immunization a low priority, perceived low risk of illness, limited knowledge and health literacy about the disease, difficulty accessing services, clinician bias, cost, or personal, and cultural or religious beliefs discouraging vaccination.

The overall goal of this NOSI is to apply scientific methods to promote the uptake of vaccination among populations who experience health disparities. This NOSI is focused on adults 18 years and older for all vaccines including eligible children and adolescents for SARS-CoV-2 and HPV-related topics (9 years and older). Effective measures and trusted sources are essential to address and reduce misinformation, build community trust, and to promote widespread vaccine dissemination, population level uptake, and adherence to vaccination protocols. Applications are encouraged to consider upstream factors (e.g., interpersonal, community, health system, policy), as well as relevant cultural and historical factors associated with individual beliefs, risk perceptions, and behavior across multiple levels (e.g., individual, community, etc.). Projects focusing on rural populations are encouraged. Applications should make explicit their rationale for the specific populations of focus and describe the disparities to be addressed. Additionally, applications on urgent topics such as the uptake and/or series completion of the SARS-CoV-2 vaccine, annual influenza vaccination, and recommended pneumococcal vaccines are encouraged.

Key questions to be addressed include but are not limited to:

  • What interventions and strategies are most effective to increase the reach, access, acceptance, and vaccine completion among populations that experience health disparities?
  • How can evidence-based interventions that have reduced vaccine hesitancy and increased both access and uptake of other vaccinations (e.g., influenza and HPV) be adapted and/or adopted to increase the uptake of the SARS-CoV-2 vaccine?
  • How can social media, digital marketing, and other innovative technologies (such as smart phone applications) be integrated into vaccine promotion interventions to identify and address the sources of misinformation and disinformation regarding vaccination?
  • How can vaccine-related communications on SARS-CoV-2, HPV, influenza, and other vaccines be generated and promoted by clinicians and healthcare systems to be community and/or culturally appropriate?
  • What are effective culturally specific and/or community competent approaches for reducing barriers and increasing vaccination uptake and completion?
  • What service delivery or organizational level policies are effective in facilitating broad vaccination uptake and reducing barriers such as stigma, distrust, fear, discrimination, and exposure to misinformation?
  • What local, state, or federal policies are effective in mitigating disparities in vaccine access, uptake, and series completion?
  • What unintended negative consequences do vaccine related policies create such as exacterbating disparities in access or vaccine series completion?
  • What are effective dissemination and implementation strategies related to vaccination in clinical and community settings?
  • What rapid data collection methods (e.g., rapid ethnographic assessments) can be used to identify and prioritize vaccine interventions in communities?

Primary Data Collection Studies

Responsive grant applications must involve a formal collaboration with one or more of the following:

  • Tribal governments and agencies;
  • Academic and community medical centers or health systems, safety-net health clinics (e.g., free clinics, federally qualified health care centers), social service systems (e.g., women infants and children [WIC] centers), public health agencies;
  • Community-based or faith-based organizations or groups, schools including Head Start locations, workplaces, childcare settings; or
  • NIH-funded SARS-CoV-2 initiatives focused on populations who experience health disparities: Community Engagement Alliance (CEAL) Against COVID-19 Disparities initiative or the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative where appropriate (i.e., population focus and/or intervention designs are similar, or study sites are geographically co-located or near the applicant’s proposed study site).

Studies are encouraged to collaborate and partner with key community stakeholders and leverage community resources and local service delivery settings to enhance vaccine access, delivery, and uptake. Applicants should have: 1) a history of successful recruitment and retention of participants within the populations of focus, 2) create sustainable collaborations and implementation in communities disproportionately affected by illnesses for which vaccination is an option; and 3) conduct effective communication, co-creation, and dissemination activities to inform communities about the project and its findings. Projects must have clearly defined roles for all partners. As appropriate, study budgets should include funds for community collaborations and partnerships to be fully engaged in research design and implementation. Approaches to engage community stakeholders through the research process, such as team science, community-engaged research, participatory action research, empowerment evaluation approaches, community asset mapping, citizen science, and community health workers are strongly encouraged.

Design, Analysis, and Sample Size for Studies to Evaluate Group-Based Interventions: Investigators who wish to evaluate the effect of an intervention on a health-related biomedical or behavioral outcome may propose a study in which (1) groups or clusters are assigned to study arms and individual observations are analyzed to evaluate the effect of the intervention, or (2) participants are assigned individually to study arms but receive at least some of their intervention in a real or virtual group or through a shared facilitator. Such studies may propose a parallel group- or cluster-randomized trial, an individually randomized group-treatment trial, a stepped-wedge design, or a quasi-experimental version of one of these designs. In these studies, special methods may be warranted for analysis and sample size estimation. Group randomization may not be feasible in some circumstances for community-based interventions among populations who experience health disparities. Applicants should use methods that are appropriate given their plans for assignment of participants and delivery of interventions. Additional information is available at https://researchmethodsresources.nih.gov/.

Applications should also delineate outcomes (such as receipt of target vaccine) and how the intervention or strategies can be sustained and scaled-up to improve population health.

Secondary Data Analysis Studies

Projects of interest may include studies evaluating the effects of vaccine mandates or other policies, e.g., analyses drawing on “natural experiments” to understand how organizational, local, state, and federal policies and initiatives mitigate or exacerbate disparities in vaccine access, uptake, and series completion.

Study Outcomes

Primary outcomes: Vaccine uptake and/or vaccine series completion, including boosters per recommendations by the CDC's Advisory Committee on Immunization Practices (https://www.cdc.gov/vaccines/acip/index.html) as applicable.

Secondary outcomes (include, but are not limited to): Vaccine hesitancy – including vaccine confidence, vaccine convenience, vaccine complacency; community/social vaccine beliefs, norms, and risk perceptions; vaccine distribution and implementation across various sectors/settings; implementation of policies to increase individual access and uptake; access to immunization services; service delivery improvements; trust in science supporting vaccine research; and distrust in government and health organizations providing vaccine recommendations.

Projects must include a focus on one or more populations whom NIH designates as experiencing health disparities in the United States, which include racial and ethnic minority groups (Blacks or African American, Hispanic or Latino, American Indian and Alaska Native, Asian American, Native Hawaiian and Pacific Islander populations), people with less privileged socioeconomic status, sexual and gender minority persons, and underserved rural populations. Please see https://www.nimhd.nih.gov/about/overview/ for more information.

Projects that examine or address factors at multiple levels are strongly encouraged (see the NIMHD Research Framework for examples of determinants of health at different levels: https://www.nimhd.nih.gov/about/overview/research-framework/nimhd-framework.html). Research is encouraged among distinct sub-populations based on the country of origin (e.g., Koreans, Vietnamese, Cambodian, etc., rather than Asian Americans). Projects are expected to incorporate research strategies to address individual and structural social determinants of health (SDOH) (https://health.gov/healthypeople/objectives-and-data/social-determinants-health) that present barriers to vaccine access and uptake.

Applications are also strongly encouraged to support early-stage investigators from diverse backgrounds, including from groups underrepresented in the biomedical research workforce.

Projects targeting access, acceptance and uptake of routine vaccines among children and adolescents, with the exception of HPV and SARS-CoV-2, are not considered within scope of this NOSI, however they may be within the scope of NICHD as described in: https://grants.nih.gov/grants/guide/notice-files/NOT-HD-21-038.html.

Research Topics:

Research topics of interest on vaccination include, but are not limited to, the following:

  • Examine interventions to reduce barriers to vaccine uptake and successful completion of the vaccine protocol.
  • Determine baseline rates of hesitancy for the SARS-CoV-2 vaccine and use this information to evaluate innovative interventions to reduce concerns, increase trust and preparedness, and facilitate uptake of the vaccine in various settings and environments (e.g., primary care settings, medical centers, reproductive health clinics, dental clinics, community health clinics, pharmacies, Tribal health facilities, schools, workplaces, pharmacies, remote care settings, and non-healthcare contexts) as administered by various staff (doctors, nurses, pharmacists, paraprofessionals, and trained community health workers).
  • Implement and test the effect of behavioral change models to increase vaccine uptake and series completion.
  • Evaluate intererventions to understand and address parental vaccine hesitancy and and examine the impact on SARS-CoV-2 or HPV vaccine uptake and series completion among children and adolescents.
  • Evaluate novel behavioral interventions leveraging digital technology to promote adherence with vaccine uptake/series completion and prevention strategies (i.e., hand washing, social distancing).
  • Evaluate the impact of organizational, local, state, and federal policies (e.g., vaccine mandates, COVID mitigation strategies, work policies) in exacerbating or mitigating disparities in vaccine access, uptake, and series completion.
  • Examine and address multilevel factors, including policies, community-level factors, health systems, interpersonal/family/professional, and individual-level variables (e.g., cognitive and behavioral factors) that maximize vaccine access, uptake, and series completion.
  • Examine and address the spread of vaccine misinformation across various social media-based platforms, cultural contexts, and interpersonal communication channels and how it relates to the uptake of vaccination.
  • Evaluate vaccine messaging through various innovative technologies to identify core features and influencers (including social influencers and key messaging) associated with vaccine adherence/uptake.
  • Examine strategies for adoption and adaptation of effective communication, education, or other engagement strategies to enhance patient-clinician communication around vaccinations and related research, including health literacy and low-English and non-English proficiency.
  • Conduct studies to test the acceptance and effectiveness of vaccine communications or behavioral interventions delivered by medical providers, scientists, clergy, community leaders, trained community health workers, or peers.
  • Examine whether and the degree to which interest and acceptance of vaccine uptake vary by real-life experience with the disease, including vaccine hesitancy among individuals who have “recovered” from COVID-19 or know others who have versus those who have lost family/friends/coworkers to COVID-19 or know others who have.
  • Apply novel predictive analytics to identify geographical areas of health disparities and resources available to concentrate successful interventions to mitigate areas of high risk for future infections and healthcare burden.
  • Identify somatic complaints and side effects and outcomes, particularly for those at higher medical risk, and medical and behavioral strategies used to decrease or prevent them and improve vaccine protocol adherence.
  • Conduct interventions using proven implementation science approaches and frameworks (e.g., RE-AIM (Reach, effectiveness, adoption, implementation, maintenance)) and examine facilitators and barriers to and fidelity of intervention delivery of vaccines.

National Cancer Institute (NCI)

NCI is interested in research strategies, policy evaluations, and interventions that focus on vaccines that prevent cancer, including the human papillomavirus (HPV) and hepatitis B (HBV) vaccines. In addition, NCI is interested in research that addresses SARS-CoV-2 vaccine hesitancy, uptake, and implementation among those directly affected by cancer, including cancer survivors (those living with cancer and those free of cancer) across the lifespan and their caregivers.

NCI FOAs for this NOSI include the following or their subsequent reissued equivalents:

Activity Code

FOA

First Available Due Date

R01

PA-20-185- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

February 5, 2022

R01

PAR-21-190 – Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

March 7, 2022

R01

PAR-21-035 – Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

February 5, 2022

R01

PAR-19-274 – Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

February 5, 2022

R01

PA-19-348 – Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)

June 8, 2022

R01

PAR-19-360 – Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)

February 5, 2022

NCI does not participate in PA-20-183- Research Project Grant (Parent R01 Clinical Trial Required).

National Institute of Dental and Craniofacial Research (NIDCR)

NIDCR supports research on vaccination programs to prevent oral diseases and conditions (e.g., HPV vaccination) as well as opportunities for dental care providers to contribute to broader public health efforts (e.g., influenza or COVID-19 vaccination), as allowable by state practice acts. For this NOSI, NIDCR is interested in research to develop improved methods of promoting vaccine uptake among groups that experience health disparities.

Areas of interest include, but are not limited to:

  • Research to understand the feasibility and acceptability of vaccine programs in dental settings among health disparity populations.
  • Research to characterize barriers to and facilitators of vaccine uptake for health disparity populations.
  • Research on the use of innovative healthcare delivery models or interventions to improve vaccine uptake within health disparity populations (e.g., Screening, Brief Intervention, and Referral to Treatment or SBIRT models; use of electronic health records to facilitate coordinated care).

Investigators proposing research that meets the NIH definition of clinical trials are strongly advised to use NIDCR’s UG3/UH3 mechanism and are encouraged to contact program staff.

Please see NOT-DE-21-014 for information about NIDCR’s clinical trials program.

National Institute on Mental Health (NIMH)

Services and Intervention Research

The NIMH Division of Services and Intervention Research is interested in research that aligns to both priorities in this NOSI and Goal #4 of the NIMH Strategic Plan for Research. All applications that propose clinical trials are required to follow the NIMH’s experimental therapeutics approach to intervention development and testing (see Support for Clinical Trials at NIMH). For further information on NIMH clinical trial policies, see NOT-MH-20-105 and NOT-MH-19-006.

  • Develop and test risk communications strategies (e.g., psychoeducation or motivational interviewing for people with mental illness) that can be employed by a provider or other care team member (e.g., care manager or peer support specialist) during a visit or as part of routine outreach to patients in order to reduce vaccine hesitancy and promote vaccine uptake.
  • Develop and test clinic or system-level nudge strategies to encourage providers and patients to proactively discuss concerns about vaccine hesitancy and identify practical barriers or facilitators that may interfere with our encourage vaccine access.
  • Evaluate implementation and use of incentives (financial or otherwise) that improve vaccine access and uptake in people with mental illness.
  • Evaluate the effect of practical strategies that make vaccines more accessible at the time and place where mental health services are delivered.
  • Address vaccine hesitancy, uptake and implementation among populations who are particularly susceptible to infection and/or poor outcomes from diseases whose risk can be substantially minimized by vaccination, such as individuals with mood disorders, psychotic disorders and other serious mental illnesses.

Applications for these research priorities should apply to PAR-21-316, PAR-19-189, PAR-21-131, or PAR-21-130.

HIV Research

The NIMH Division of AIDS Research encourages research that will support the conduct of HIV vaccine clinical trials or inform future acceptance and uptake of HIV vaccines among populations who would benefit. This includes vaccines developed for HIV prevention as well as HIV therapeutic vaccines that seek to improve HIV treatment outcomes. Applications may focus on areas that include but are not limited to: basic behavioral and social science to understand the contemporary HIV vaccine communications landscape and associated influences; novel strategies for engaging communities who may benefit from a future HIV vaccine; and understanding as well as addressing HIV vaccine misinformation and hesitancy. NIMH will only prioritize applications involving current vaccines (e.g., COVID-19, HPV, HBV vaccines) to the extent that they make HIV vaccine-relevant populations, providers, and settings the primary focus of the research and can clearly inform and support HIV vaccine research. Applicants are strongly encouraged to consult the NIMH staff contacts listed on this NOSI early in the application development process to best match current institute priorities.

For further information on the NIMH Division of AIDS Research priorities, see the NIMH Division of AIDS Research webpage.

Examples of research topics include, but are not limited to:

  • Research which seeks to identify important sources of communication related to HIV vaccines (and vaccines in general) in the daily life of key populations placed at risk for HIV, and whether and how these communications influence understanding, acceptance, and uptake of future HIV vaccines
  • Studies that evaluate how influences on HIV vaccine communication and subsequent outcomes vary by audience, particularly between different key populations
  • Communication research to understand and advance participant screening and enrollment in HIV vaccine trials
  • Developing culturally, developmentally, and linguistically appropriate health literacy tools to facilitate HIV vaccine trial participation and retention, and to ethically address HIV vaccination risk, safety, and trust
  • Intervention development research to craft communication tools and approaches to support understanding, acceptance, and uptake of future HIV vaccines among key populations placed at risk for HIV
  • Studies advancing developmentally appropriate interventions designed to promote vaccine acceptance and uptake among youth placed at risk
  • Research to evaluate multilevel contributors to vaccine hesitancy that examine communication at the policy, community, and systems levels
  • Studies of the role of digital technologies and social media on vaccine messaging/information and the spread of misinformation among populations who would benefit from an HIV vaccine.

Applications for these research priorities should apply to PA-20-145, PA-20-141, or PA-20-144.

NIMH will only accept applications submitted through these FOAs or their subsequent reissued equivalents:

Activity Code

FOA Title

First Available Due Date

R01

PAR-21-316- Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)

May 25, 2022

R34

PAR-19-189 - Pilot Services Research Grants Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)

May 25, 2022

R34

PAR-21-131 - Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)

May 25, 2022

R01

PAR-21-129- Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)

May 25, 2022

R01

PAR-21-130 - Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)

May 25, 2022

R21

PA-20-145 - Innovations in HIV Prevention, Testing, Adherence, and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)

May 7, 2022

R34

PA-20-141- Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 Clinical Trial Optional)

May 7, 2022

R01

PA-20-144 - Innovations in HIV Prevention, Testing, Adherence, and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)

May 7, 2022

Office of Disease Prevention (ODP)

The ODP is the lead office at the NIH responsible for assessing, facilitating, and stimulating research in disease prevention. In partnership with the 27 NIH Institutes and Centers, the ODP strives to increase the scope, quality, dissemination, and impact of NIH-supported prevention research. The ODP is interested in providing co-funding support for research that has strong implications for disease and injury prevention and health equity and that include innovative and appropriate research design, measurement, and analysis methods. Furthermore, the ODP has a specific interest in projects that develop and/or test preventive interventions. For this NOSI, ODP is interested in research that addresses vaccine hesitancy, uptake, and implementation strategies of vaccines among populations that experience health disparities and that address topics relevant to the mission and research priorities outlined in the ODP strategic plan. For additional information about ODP’s research priorities and interests, please refer to the ODP Strategic Plan for Fiscal Years 2019–2023.

Office of Research on Women's Health (ORWH)

ORWH is part of the Office of the Director of NIH and works in partnership with the 27 NIH Institutes and Centers to ensure that women's health research is part of the scientific framework at the NIH and is supported in the larger scientific community. Researchers studying trends in vaccination coverage over time reveals substantial differences in uptake, with low income, racial and ethnic minority-, and geographically isolated and resource-poor communities having lower vaccination rates. Historically having had limited opportunities for economic, physical, and emotional health, these are the communities most affected by and vulnerable to viral pathogens including but not limited to SARS-CoV-2 and HPV. To prevent the spread of disease, safe and effective vaccines must be both acceptable and accessible to all. To further acceptability, both research and outreach communications seeking to enhance vaccine confidence and promote vaccination coverage should be designed in a sex and gender-sensitive way.

Clinical research studies have shown sex differences in some vaccine responses, including vaccine efficacy and adverse events. Also, there is an ongoing need to work towards equity in the distribution and uptake of immunization for vaccine-preventable diseases. ORWH is interested in providing support for interdisciplinary, behavioral, clinical, and/or translational studies incorporating intersectional analyses of sex and gender differences in vaccine hesitancy and immunization uptake among populations experiencing health disparities, including groups of women who are understudied, underrepresented, and underreported in research. Proposals seeking to shed light on an array of dimensions where the inequities exist (i.e., household/caregiving responsibility inequities; disparities related to healthcare, housing inequities, and sexual and reproductive health) and their impact on preventive measure adoption are of particular interest. For additional guidance, please refer to the 2019-2023 Trans-NIH Strategic Plan for the Health of Women on the ORWH website (https://www.nih.gov/women/strategicplan).

Maximizing comparisons across datasets or studies and data integration are essential for collaboration. Projects funded through this NOSI are strongly encouraged to use the following resources:

  • Data Harmonization for SDOH via the PhenX Toolkit: Investigators involved in human-subject studies are strongly encouraged to employ a common set of tools and resources that will promote the collection of comparable data on SDOH across studies. Studies should incorporate measures from the Core and Specialty collections that are available in the SDOH Collection of the PhenX Toolkit (www.phenxtoolkit.org).
  • Existing COVID-19 survey items and investigator contact information are publicly available through two NIH-supported platforms: the NIH Public Health Emergency and Disaster Research Response (DR2) [https://dr2.nlm.nih.gov/] and the PhenX Toolkit. Researchers addressing COVID-19 questions, whether population-based or for clinical research, are strongly encouraged to consider these COVID-19 specific survey item repositories and select existing survey items or protocol modules currently being fielded.

Additionally, researchers with funding through this NOSI will be strongly encouraged to share their survey items to make them public for other researchers to consider by submitting their surveys to NIHCOVID19Measures@nih.gov.

Applications not responsive to the NOSI:

  • Projects without a primary focus on vaccine uptake or completion outcomes among one or more NIH-designated population with health disparities.
  • Projects examining vaccine uptake/completion outside of the U.S. or its territories.
  • Projects focused on individuals under age 18, with the exception of projects focused on the SARS-CoV-2 or HPV vaccines which may include eligible children and adolescents.

Applications nonresponsive to these terms will be withdrawn for this NOSI initiative.

Application and Submission Information

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

  • PA-20-183- Research Project Grant (Parent R01 Clinical Trial Required)
  • PA-20-185- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

  • For funding consideration, applicants must include “NOT-MD-22-006” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4b will not be considered for this initiative.

Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with Scientific Research Contacts listed on this NOSI well in advance of the anticipated submission date to better determine appropriateness and interest of the IC.

Applications nonresponsive to terms of this NOSI will be withdrawn from consideration for this initiative.

Inquiries

Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:

Scientific/Research Contact(s)

Integrative Biological and Behavioral Sciences

Deborah E. Linares, Ph.D., M.A.
National Institute on Minority Health and Health Disparities (http://www.nimhd.nih.gov)
Telephone: 301-402-2516
Email: deborah.linares@nih.gov

Clinical and Health Services Research

Rada K Dagher, Ph.D., M.P.H.
National Institute on Minority Health and Health Disparities (http://www.nimhd.nih.gov)
Telephone: 301-451-2187
Email: rada.dagher@nih.gov

Community Health and Population Sciences

Nancy L. Jones, Ph.D., M.A.
National Institute on Minority Health and Health Disparities (http://www.nimhd.nih.gov)
Telephone: 301-594-8945
Email: nancy.jones@nih.gov

Robin Vanderpool, Dr.P.H.
National Cancer Institute (NCI)
Telephone: 240-276-6558
Email: robin.vanderpool@nih.gov

Barbara L. Mulach, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Phone: 240-627-3322
E-mail: bmulach@niaid.nih.gov

Julia Beth Zur
National Institute On Drug Abuse (NIDA)
Phone: 301-443-2261
E-mail: julia.zur@nih.gov

Margaret Grisius, DDS
National Institute Of Dental & Craniofacial Research (NIDCR)
E-mail: margaret.grisius@nih.gov

Collene Lawhorn, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-828-7186
Email: collene.lawhorn@nih.gov

Michael J. Stirratt, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 240-627-3875
Email: stirrattm@nih.gov

Dionne Godette-Greer, Ph.D.
National Institute of Nursing Research (NINR)
Email: dionne.godette@nih.gov

Jacqueline Lloyd, PhD, MSW
Senior Advisor for Disease Prevention
Office of Disease Prevention
Telephone: 301-827-5559
Email: lloydj2@nih.gov

Damiya Eve Whitaker
Office of Research On Women's Health (ORWH)
Phone: 240-276-6170
E-mail: damiya.whitaker@nih.gov

Christopher Barnhart, PhD
Sexual & Gender Minority Research Office (SGMRO)
Telephone: 301-594-8983
Email: christopher.barnhart@nih.gov

Julia Zur, Ph.D.
Division of Epidemiology, Prevention, and Services Research
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-2261
Email: julia.zur@nih.gov

Financial/Grants Management Contact(s)

Priscilla Grant, J.D.
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-8412
Email: grantp@mail.nih.gov

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: (240) 276-6277
E-mail: wolfreyc@mail.nih.gov

Vandhana Khurana, MBA
National Institute of Allergy and Infectious Diseases (NIAID)
Phone: 240-669-2966
Email:vandhana.khurana@nih.gov

Pamela G Fleming
National Institute On Drug Abuse (NIDA)
Phone: 301-480-1159
E-mail: pfleming@mail.nih.gov

Diana Rutberg, MBA
National Institute Of Dental & Craniofacial Research (NIDCR)
Phone: (301) 594-4798
E-mail: dr258t@nih.gov

Rita Sisco
National Institute of Mental Health (NIMH)
Telephone: 301-443-2805
Email: siscor@mail.nih.gov

Ron Wertz
National Institute of Nursing Research (NINR)
Telephone: 301-594-2807
Email: wertzr@mail.nih.gov

Pam Fleming
National Institute on Drug Abuse
Telephone: 301-480-1159
Email: pfleming@mail.nih.gov